CR9209A - Anticuerpos frente al receptor alfa-1 de la il-13 y usos de los mismos - Google Patents

Anticuerpos frente al receptor alfa-1 de la il-13 y usos de los mismos

Info

Publication number
CR9209A
CR9209A CR9209A CR9209A CR9209A CR 9209 A CR9209 A CR 9209A CR 9209 A CR9209 A CR 9209A CR 9209 A CR9209 A CR 9209A CR 9209 A CR9209 A CR 9209A
Authority
CR
Costa Rica
Prior art keywords
alfa
receiver
same
antibodies against
antibody
Prior art date
Application number
CR9209A
Other languages
English (en)
Inventor
Endl Josef
Fuentes Maria
Graus Yvo
Grossmann Adelbert
Parren Paul
Rebers Frank
Regula Joerg
Schumacher Ralf
Seeber Stefan
Stracke Jan
Stubenrauch Kay-Gunnar
Van De Winkel Jan
Van Vugt Martine
Vereecken-Verploegen Sandra
Neumann Sebastian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR9209A publication Critical patent/CR9209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un anticuerpo con union a IL-l3R?l, inhibiendo la bioactividad de IL-13 y que contiene unas cadenas variables pesada y ligera, caracterizadas por que la secuencia de aminoacidos de la region variable de la cadena pesada CD3 de dicho anticuerpo es seleccionada a partir del grupo de secuencias de cadena pesada CD3 con N° de ID SEC: 1, 3, 5, 7 o 9 es util en el tratamiento del asma y las enfermedades respiratorias.
CR9209A 2005-01-03 2007-06-26 Anticuerpos frente al receptor alfa-1 de la il-13 y usos de los mismos CR9209A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05000003 2005-01-03
EP05002229 2005-02-03

Publications (1)

Publication Number Publication Date
CR9209A true CR9209A (es) 2007-08-28

Family

ID=36199730

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9209A CR9209A (es) 2005-01-03 2007-06-26 Anticuerpos frente al receptor alfa-1 de la il-13 y usos de los mismos

Country Status (19)

Country Link
US (2) US7807158B2 (es)
EP (1) EP1836226B1 (es)
JP (1) JP5086098B2 (es)
KR (1) KR100934894B1 (es)
AR (1) AR051888A1 (es)
AT (1) ATE513855T1 (es)
AU (1) AU2006204480B2 (es)
BR (1) BRPI0606368A2 (es)
CA (1) CA2592614C (es)
CR (1) CR9209A (es)
IL (1) IL184205A0 (es)
MA (1) MA29226B1 (es)
MX (1) MX2007008128A (es)
NO (1) NO20073655L (es)
NZ (1) NZ556126A (es)
RU (1) RU2413736C2 (es)
SG (1) SG172504A1 (es)
TW (2) TW200902555A (es)
WO (1) WO2006072564A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
LT2769992T (lt) * 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008049098A2 (en) 2006-10-19 2008-04-24 Merck & Co., Inc. ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
EP2068921B1 (en) 2006-10-19 2014-07-09 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
DK2068922T3 (da) * 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
MX2009012786A (es) 2007-06-01 2009-12-10 Hoffmann La Roche Purificacion de inmunoglobulina.
CA2693611A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
ES2695999T3 (es) 2007-10-12 2019-01-11 Hoffmann La Roche Expresión de proteínas a partir de múltiples ácidos nucleicos
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8227195B2 (en) 2007-12-15 2012-07-24 Hoffman-La Roche Inc. Distinguishing assay
HRP20150965T1 (hr) * 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
WO2010131704A1 (ja) * 2009-05-13 2010-11-18 塩野義製薬株式会社 内臓脂肪型肥満の検査薬およびその利用
CA2768326C (en) 2009-07-30 2019-01-08 F. Hoffmann-La Roche Ag Moveable chromatography column separator
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
PT2483305T (pt) 2009-10-01 2016-11-04 Hoffmann La Roche Filtração final de imunoglobulina em várias etapas
CN105624118B (zh) 2009-10-19 2019-08-13 弗·哈夫曼-拉罗切有限公司 非交叉反应性抗IgG抗体
BR112012012873B1 (pt) 2009-12-22 2021-08-31 F.Hoffmann-La Roche Ag Método para fornecer uma sequência de ácido nucleico que codifica uma imunoglobulina e método para produzir uma imunoglobulina
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
JP6073811B2 (ja) 2011-02-02 2017-02-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ クロマトグラフィーカラムサポート
WO2012145746A1 (en) * 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
EP4124624A3 (en) 2013-12-20 2023-05-03 Intervet International B.V. Antibodies against canine pd-1
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CA2961987A1 (en) 2014-09-30 2016-04-07 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP7073253B2 (ja) * 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
ES2877532T3 (es) 2015-08-21 2021-11-17 Hoffmann La Roche Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
WO2018011405A1 (en) * 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3947457A1 (en) 2019-03-26 2022-02-09 ASLAN Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
CA3147436A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
EP4590335A1 (en) 2022-08-26 2025-07-30 ASLAN Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
US20260078192A1 (en) 2022-09-06 2026-03-19 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE69638050D1 (de) 1995-10-23 2009-11-19 Zenyth Operations Pty Ltd Hemopoietin-rezeptor und dafür kodierende genetische sequenzen
US5843659A (en) * 1996-03-21 1998-12-01 Apoptosis Technology, Inc. Apoptosis gene EI24, compositions, and methods of use
JPWO2003046009A1 (ja) * 2001-11-27 2005-04-07 持田製薬株式会社 抗ＩＬ１３レセプターα１中和抗体
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
JP4432031B2 (ja) 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
US7625699B2 (en) * 2003-03-10 2009-12-01 Celera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof
MEP31508A (hr) * 2003-07-15 2010-10-10 Amgen Inc Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade

Also Published As

Publication number Publication date
TW200902555A (en) 2009-01-16
AR051888A1 (es) 2007-02-14
KR100934894B1 (ko) 2010-01-07
CA2592614C (en) 2015-04-14
KR20070091180A (ko) 2007-09-07
HK1112006A1 (en) 2008-08-22
TWI306862B (en) 2009-03-01
BRPI0606368A2 (pt) 2009-06-23
JP2008526187A (ja) 2008-07-24
NO20073655L (no) 2007-08-02
MX2007008128A (es) 2007-07-20
CA2592614A1 (en) 2006-07-13
US20110086026A1 (en) 2011-04-14
US20060263356A1 (en) 2006-11-23
JP5086098B2 (ja) 2012-11-28
RU2413736C2 (ru) 2011-03-10
EP1836226A1 (en) 2007-09-26
WO2006072564A1 (en) 2006-07-13
IL184205A0 (en) 2007-10-31
NZ556126A (en) 2008-09-26
EP1836226B1 (en) 2011-06-22
TW200635945A (en) 2006-10-16
RU2007129676A (ru) 2009-02-10
ATE513855T1 (de) 2011-07-15
MA29226B1 (fr) 2008-02-01
AU2006204480A1 (en) 2006-07-13
AU2006204480B2 (en) 2011-06-09
SG172504A1 (en) 2011-07-28
US7807158B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
AR051888A1 (es) Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20121361A1 (es) Antagonistas de pcsk9
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
RU2013133802A (ru) Стабильные и растворимые антитела, ингибирующие vegf
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20061395A1 (es) Anticuerpos contra miostatina
NZ597692A (en) Anti-IGF antibodies
SI1557462T1 (sl) Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
PE20081478A1 (es) Anticuerpos cd44
CO6230999A2 (es) Anticuerpo anti-esclerostina
RU2013138469A (ru) АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
EA200800812A1 (ru) Композиции антитела против cd3
PE20142041A1 (es) Anticuerpos anti-il-36r
ATE403680T1 (de) Herstellung tetravalenter antikörper
NZ755083A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)